Kura Oncology Announces Commencement of Public Offering of Common Stock
August 09 2017 - 4:17PM
Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage
biopharmaceutical company focused on the development of precision
medicines for oncology, today announced that it has commenced an
underwritten public offering, subject to market and other
conditions, to issue and sell up to 5,300,000 shares of its common
stock. In connection with the offering, Kura Oncology expects
to grant the underwriters a 30-day option to purchase up to an
additional 795,000 shares of its common stock. There can be
no assurance as to whether or when the offering may be completed,
or as to the actual size or terms of the offering.
Leerink Partners and Cowen are acting as joint
book-running managers in the offering. JMP Securities and
Oppenheimer & Co. are acting as co-lead managers.
The securities described above are being offered
by Kura Oncology pursuant to a shelf registration statement on Form
S-3, including a base prospectus, that was previously filed by Kura
Oncology with the Securities and Exchange Commission (the “SEC”)
and that was declared effective on April 14, 2016. A
preliminary prospectus supplement and accompanying prospectus
relating to the offering will be filed with the SEC and will be
available for free on the SEC’s website located at
http://www.sec.gov. Copies of the preliminary prospectus supplement
and the accompanying prospectus relating to the offering, when
available, may be obtained from Leerink Partners LLC,
Attention: Syndicate Department, One Federal Street, 37th
Floor, Boston, MA 02110, or by telephone at (800) 808-7525,
ext. 6132, or by email at syndicate@leerink.com; or from Cowen
and Company, LLC, c/o Broadridge Financial Services, Attention:
Prospectus Department, 1155 Long Island Avenue, Edgewood, NY,
11717, or by telephone at (631) 274-2806 or by fax at (631)
254-7140.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy these securities,
nor shall there be any sale of these securities in any state or
other jurisdiction in which such offer, solicitation or sale would
be unlawful prior to the registration or qualification under the
securities laws of any such state or other jurisdiction.
About Kura Oncology
Kura Oncology is a clinical-stage
biopharmaceutical company committed to realizing the promise of
precision medicines for the treatment of cancer. Kura Oncology’s
pipeline consists of small molecule drug candidates that target
cancer signaling pathways where there is a strong scientific and
clinical rationale to improve outcomes by identifying those
patients most likely to benefit from treatment. Kura Oncology’s
lead drug candidate is tipifarnib, a farnesyl transferase
inhibitor, which is currently being studied in multiple Phase 2
clinical trials. Kura Oncology’s pipeline also includes KO-947, an
ERK inhibitor, currently in a Phase 1 trial, and KO-539, an
inhibitor of the menin-MLL protein-protein interaction, currently
in preclinical testing.
Forward-Looking Statements
Statements contained in this press release
regarding matters that are not historical facts are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Such
forward-looking statements include, without limitation, statements
about Kura Oncology’s expectations regarding the completion, timing
and size of the proposed offering, and its expectations with
respect to granting the underwriters a 30-day option to purchase
additional shares. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Words such
as “believes,” “anticipates,” “plans,” “expects,” “intends,”
“will,” “goal,” “potential” and similar expressions are intended to
identify forward-looking statements. These forward-looking
statements are based upon Kura Oncology’s current expectations and
involve assumptions that may never materialize or may prove to be
incorrect. Actual results and the timing of events could
differ materially from those anticipated in such forward-looking
statements as a result of various risks and uncertainties, which
include, without limitation, risks associated with market
conditions and the satisfaction of closing conditions related to
the proposed public offering, as well as risks and uncertainties
associated with Kura Oncology’s business and finances in general,
and the other risks described in Kura
Oncology’s quarterly report on Form 10-Q for the quarter
ended June 30, 2017 and other filings with
the SEC. All forward-looking statements contained in
this press release speak only as of the date on which they were
made. Kura Oncology undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made.
Investor Relations Contact:
Robert H. Uhl
Managing Director
Westwicke Partners, LLC
(858)-356-5932
robert.uhl@westwicke.com
Corporate Communications Contact:
Mark Corbae
Vice President
Canale Communications
(619) 849-5375
mark@canalecomm.com
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Apr 2023 to Apr 2024